NCT01322321

ACZ885 in Type 1 Diabetes Mellitus

A Randomized, Double-blind, Multiple-dose, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ACZ885 in Patients With Newly Diagnosed Type-1 Diabetes Mellitus (T1DM)

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 6 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.

Conditions

• Diabetes Mellitus
• Diabetes Type 1

Interventions

Type	Name	Description
DRUG	ACZ885
DRUG	Placebo

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-06-01
• First posted: 2011-03-24
• Last updated: 2012-09-05

Locations

10 sites across 4 countries: United States, Canada, Germany, United Kingdom